A phase IIa trial of durvalumab in combination with tumor-infiltrating lymphocytes in patients with metastatic melanoma

Trial Profile

A phase IIa trial of durvalumab in combination with tumor-infiltrating lymphocytes in patients with metastatic melanoma

Planning
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tumour infiltrating lymphocytes (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
    • 23 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top